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Objectives: Neopterin, a marker of inflammation and monocyte activation, is found increased in patients
with heart failure (HF). This study investigates whether neopterin levels correlate with left ventricular (LV)
remodeling and brain natriuretic peptide (BNP), a marker of cardiac stress, in chronic HF (CHF) patients with
different severity of disease.
Design and methods: The relationship between neopterin and LV dimensions, NT-proBNP, and
pro-inflammatory cytokines were studied in 98 CHF patients, while nineteen healthy subjects were enrolled
as controls. Nineteen (19%) patients were in NYHA class I, 38 (39%) in NYHA class II, 27 (28%) in NYHA class
III, and 14 (14%) in NYHA class IV.
Results: Neopterin levels were higher in CHF patients than in age- and gender-matched healthy controls,
and related with indexed LV end-diastolic volume (LVEDVi). Prospectively CHF patients were separated into
tertiles of low, medium and high neopterin levels. Among patients, male gender, LVEDVi, diuretic treatment,
NYHA class I, NT-proBNP and IL-8 levels were significant determinants of urine neopterin levels by bivariate
analysis. Neopterin levels were associated only to LV remodeling, as assessed by LVEDVi, and IL-8 levels, a
crucial monocyte chemoattractant, by multivariate ordinal regression analysis.
Conclusions: The relationship between elevated neopterin levels and LV enlargement in CHF patients
suggests a crucial role of monocyte activation in the development of cardiac dysfunction in CHF patients.
Assessment of neopterin levels is a potential biomarker to evaluate the progression of LV remodeling in
CHF patients.© 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.Introduction
Although the neurohormonalmechanisms are known to be critically
involved in the development of chronic heart failure (CHF), a state of
immune activation with persistent expression of pro-inflammatory
cytokines has also been demonstrated to contribute to the exacerbation
of HF [1,2]. Several studies suggest that activated monocytes are in-
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stimated glomerular filtration
pathic dilated cardiomyopathy;
ar end-diastolic volume index;
r, neopterin to creatinine ratio;
w York Heart Association; OR,
tracellular adhesion molecule;
hysiology, CardioThoracic and
a Ospedale Maggiore, 3, 20162
(R. Caruso).
ociety of Clinical Chemists. Publisheprogression of cardiac dysfunction [3,4] and to matrix remodelling in
acute myocardial infarction (AMI) [5]. Production of pro-inflammatory
cytokines, such as interleukin (IL)-6, IL-8 and tumor necrosis factor
alpha (TNF)-α, potentially affecting left ventricular (LV) remodeling
[6], has been also attributed to secretion by mononuclear cells. High
circulating levels of chemoattractant of monocytes, such as IL-8, were
observed in congestive HF patients [7] and in CHF patients in
New York Heart Association (NYHA) class IV [8].
Neopterin, an aromatic pteridine mainly synthesized by activated
monocytes, is a marker of inflammation, immune system activation
and an active participant in cardiovascular diseases [9]. Its assessment
is proposed as potential tool useful for risk stratification of patients
with AMI [10], for prediction of 1-year LV remodeling in patients
with ST-segment elevation AMI [11], and as independent predictor
of HF hospitalization after an acute coronary syndrome [12]. High
serum neopterin levels were found in CHF patients with elevated
NYHA class [13] and were associated with high rates of cardiac events
in HF patients [14]. In patients with critical limb ischemia, the cardiac
rhythm disturbances and ischemic electrocardiographic changesd by Elsevier Inc. All rights reserved.
Table 1
Coefficients of variation of intra- and inter-assays.
Intra-assay Inter-assay
Parameter Control
Levels
Concentration
of controls
CV
(%)
n Concentration
of controls
CV
(%)
N
IL-6 (pg/mL) Low 1.2 5.8 20 1.5 9.6 20
High 10.0 3.0 20 13.0 7.7 20
IL-8 (pg/mL) Low 3.5 6.6 20 4.2 11.5 20
High 22.0 4.5 20 25.0 6.3 20
sICAM-1 (ng/mL) Low 4.5 3.6 20 4.5 6.8 40
High 20.0 5.0 20 20.0 4.4 40
CRP (mg/dL) Low 0.16 1.0 21 0.15 3.3 21
High 1.84 0.5 21 3.91 1.9 21
Neo/Cr (μmol/mol) Low 100.0 0.3 20 100.0 1.8 15
High 300.0 0.2 20 300.0 1.4 15
NT-proBNP (ng/L) Low 82.0 2.6 21 77.0 1.8 60
High 2318.0 1.2 21 2105.0 1.2 60
CRP=C-reactive protein; CV=coefficient of variation; IL=interleukin; Neo/Cr=
neopterin normalized by creatinine; NT-proBNP=N terminal pro-brain natriuretic
peptide; sICAM-1=soluble intercellular adhesion molecule type I.
95R. Caruso et al. / Clinical Biochemistry 46 (2013) 94–98were related to inflammatory mediators, specifically to circulating
neopterin levels that correlated with echocardiographic signs of
congestive HF [15].
These findings strongly suggest that enhanced activation of the
monocyte-macrophage system may play a role in LV remodeling in
CHF patients, probably by secretion of pro-inflammatory cytokines.
Thus the purposes of this study were: 1) to assess whether neopterin
levels were associated with LV remodeling and circulating levels of
pro-inflammatory cytokines, and 2) to compare the neopterin levels
with NT-pro-Brain natriuretic peptide (NT-proBNP), recognized as
cardiac stress marker, in relation to LV dimensions, in CHF patients
with different clinical severity of HF.
Materials and methods
Patients
We studied 98 patients with myocardial dysfunction secondary to
ischemic or idiopathic dilated cardiomyopathy (IDC), who had been
admitted for routine re-evaluation or for treatment of advanced HF
at the Cardiovascular Department of Niguarda Hospital from June
2010 to November 2011. None of the patients included in the
study had acute myocarditis, primary pulmonary hypertension, irre-
versible renal or hepatic failure due to hepatic-renal chronic disease,
uncontrolled diabetes mellitus, severe peripheral vascular or cerebro-
vascular disease, coexisting active neoplasia, pregnancy and alcohol/
drug abuse. At the time of enrollment, baseline clinical and cardiac
imaging data were collected. Urine and peripheral blood samples
were drawn and immediately processed, and plasma and urine
aliquots were frozen at −80 °C for measurement of biomarkers.
Nineteen healthy subjects with normal regional and global LV
function were enrolled as control group.
The study protocol was approved by the Local Ethics Committee.
All subjects gave written informed consent to participate in the study.
Definitions of clinical and instrumental measures
Clinical cardiac derangement was defined according to the NYHA
classification provided separately by two attending cardiologists (MF
and AV). Full agreement in class definition was attained in all cases.
Transthoracic echocardiograms were performed with a Vivid 7 (GE
Healthcare, London, United Kingdom) or iE33 (Philips Healthcare,
Best, Netherlands); LV end-systolic and end-diastolic volumes (LVESV
and LVEDV, respectively) were measured from four-chamber and
two-chamber apical views means of Simpson's method. For LV volume
analysis, intraobserver and interobserver variability were 6% and 8%,
respectively.
Renal function was assessed by estimated glomerular filtration
rate (eGFR) using the abbreviated MDRD formula [16].
Biochemical assays
Blood and urine samples were drawn in themorning in fasting state
to determine levels of inflammatory mediators [plasma IL-6, IL-8, solu-
ble intracellular adhesion molecule (sICAM)-1, serum C-reactive
protein (CRP), and urine neopterin] and of serumNT-proBNP by techni-
cians unaware of clinical status of patients.
Plasma IL-6, IL-8 and sICAM-1 levels were measured by enzyme-
linked immunosorbent assays (R&D Systems, Minneapolis, MN-USA).
Serum CRP concentrations were measured using a Roche/Hitachi
917 Analyzer by high-sensitive immuno-nephelometric method
(Roche Diagnostic GmbH, Mannheim, Germany).
Urinary neopterin concentrations were measured by an isocratic
high-pressure liquid chromatography (HPLC) method and were
normalized by urine creatinine concentrations (Neo/Cr). Briefly, urine
samples, stored at−20 °Cwere thawed and centrifuged; the surnatantwas then adequately diluted with chromatographic mobile phase
(15 mM of K2HPO4, pH 3.0). Neopterin and creatinine levels were
measured using a Kontron instrument (pump 422-S, autosampler
465) coupled to a fluorimetric detector (JASCO FP-1520, λex=355 nm
and at λem=450 nm) for neopterin detection and to a UV–VIS de-
tector (BIO-RAD 1706, λ=240 nm) for creatinine determination.
Neopterin and creatinine separations were performed at 50 °C on a
5 μm Discovery C18 analytical column (250×4.6 mm I.D., Supelco,
Sigma-Aldrich) at flow rate of 0.9 mL/min. The calibration curves
were linear over the range of 0.125–1 μmol/L and of 1.25–10 mmol/L
for neopterin and creatinine levels, respectively.
Serum NT-proBNP levels were measured by the ADVIA Centaur
assay (Siemens Healthcare Diagnostics).
Intra-assay and inter-assay coefficients of variation (CV) of inves-
tigated biomarkers are reported in Table 1.
Statistical analysis
Data are expressed as median (25th–75th percentile) or frequency
(percentage). Categorical variables were compared using the chi-
square test or Fisher exact test when appropriate. Continuous vari-
ables were compared between groups using Student's t-test or the
Mann–Whitney U-test, according to whether variables were normally
distributed or not, as tested by the Kolmogorov–Smirnov test. Pro-
spectively CHF patients were distributed into three groups according
to the tertile of Neo/Cr levels. Ordinal logistic regression analysis was
used to examine the association between neopterin tertiles (depen-
dent variable) and clinical, echocardiographic and inflammatory vari-
ables only in HF patients. We established a multivariate ordinal
logistic model which included only variables that were significantly
related to neopterin (significance level set at pb0.05). Results are
presented as odds ratio (OR), and their 95% confidence interval (CI).
A two tailed pb0.05 was considered statistically significant.
Results
Characteristics findings in patients with LV dysfunction and controls
The population in this study has been described in Table 2. Briefly
an average age of the patients was 56 years, 17% were female.
Fifty-six patients (57%) had a diagnosis of post-ischemic LV dysfunc-
tion. Nineteen (19%) patients were in NYHA class I, 38 (39%) patients
were in NYHA class II, 27 (28%) in class III, and 14 (14%) in class IV.
Cardiac volumes were higher in patients compared to healthy sub-
jects. Moreover, forty-two patients (43%) showed LVEDV index
(LVEDVi) ≥97 mL/m2, reflecting severe grade of LV remodeling
Table 2
Clinical and biochemical characteristics between patients and controls.
Controls (n=19) CHF patients (n=98) p
Age, years 50 (33–61) 56 (49–63) 0.076
Male, n (%) 13 (68) 81 (83) 0.204
BMI, kg/m2 25.8 (24.7–27.8) 25.3 (23.4–29.4) 0.726
LVEDVi, mL/m2 47 (42–56) 91 (64–117) b0.001
LVESVi, mL/m2 17 (15–19) 69 (56–93) b0.001
NYHA class, n (%)
III+IV 0 (0) 41 (42) b0.001
Therapy, n (%)
ACEi 4 (21) 62 (63) 0.001
β-Blocker 2 (11) 77 (79) b0.001
Statin 2 (11) 56 (57) b0.001
Antiplatelets 0 (0) 61 (63) b0.001
Diuretic 1 (5) 71 (72) b0.001
Smoking, n (%) 2 (11) 11 (11) 1.000
Hypertension, n (%) 7 (37) 34 (35) 1.000
Diabetes mellitus, n (%) 4 (21) 25 (25) 0.779
eGFR, mL/min/1.73 m2 100 (84–124) 81 (68–104) 0.028
NT-proBNP, ng/L 19 (12–54) 910 (291–2824) b0.001
Inflammatory variables
C-reactive protein, mg/dL 0.25 (0.10–0.45) 0.20 (0.10–0.50) 0.809
IL-6, pg/mL 0.53 (0–0.72) 1.80 (0.17–3.22) b0.001
IL-8, pg/mL 2.9 (2.5–3.5) 3.9 (2.8–5.1) 0.038
sICAM-1, ng/mL 154 (122–185) 188 (139–242) 0.021
Neo/Cr, μmol/mol 120 (100–210) 183 (142–250) 0.001
Data are expressed as median (25th–75th percentile) or frequency (percentage).
ACEi=angiotensin converting enzyme inhibitor; BMI=Bodymass index; eGFR=estimated
glomerular filtration rate; IL=interleukin; LVEDVi=left ventricular end-diastolic volume
index; LVESVi=left ventricular end-systolic volume index; Neo/Cr=neopterin normalized
by creatinine; NT-proBNP=N terminal pro-brain natriuretic peptide; NYHA=New York
Heart Classification; sICAM-1=soluble intercellular adhesion molecule type I.
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controls (Table 2).
All patients were taking optimal tolerated medical treatment in-
cluding ACE-inhibitors, β-blockers, diuretics, and statins.Table 3
Bivariate ordinal logistic regression analysis vs tertiles of Neopterin.
aTertiles of Neo/Cr levels
I (n=32) II (n=34)
Age, years 54 (47–64) 57 (49–64)
Male, n (%) 30 (94) 28 (82)
BMI, kg/m2 27 (23–30) 28 (24–30)
LVEDVi, mL/m2 76 (51–102) 97 (76–117)
LVESVi, mL/m2 63 (47–82) 71 (57–90)
NYHA class, n (%)
I 12 (38) 5 (15)
II 11 (34) 16 (47)
III 6 (19) 11 (32)
IV 3 (9) 2 (6)
IHD, n (%) 19 (59) 23 (68)
Therapy, n (%)
ACEi 19 (59) 22 (65)
Β-Blocker 25 (78) 26 (77)
Statin 23 (72) 22 (65)
Antiplatelets 19 (59) 25 (74)
Diuretic 17 (53) 27 (79)
Smoking, n (%) 5 (16) 2 (6)
Hypertension, n (%) 12 (38) 8 (24)
Diabetes mellitus, n (%) 7 (22) 9 (27)
eGFR, mL/min/1.73 m2 85 (76–113) 78 (62–105)
NT-proBNP, ng/L 294 (126–904) 888 (505–2870)
Inflammatory variables
C-reactive protein, mg/dL 0.10 (0.10–0.30) 0.20 (0.10–0.60)
IL-6, pg/mL 1.47 (0.71–1.77) 2.04 (1.50–3.58)
IL-8, pg/mL 3.67 (2.42–4.23) 4.10 (2.79–5.02)
sICAM-1, ng/mL 162 (137–199) 208 (148–250)
Data are expressed as median (25th–75th percentile). For abbreviations see Table 2.
a Tertiles of Neo/Cr levels: I, (first) tertile: 126 (107–142) μmol/mol; II (second) tertile:Controls’median age was 50 years (33–61), 6 subjects (32%) were
female. All control subjects had a LVEF >55%. Smoking habit, hyper-
tension, and diabetes mellitus were similarly represented in controls
and HF patients, while renal function, evaluated by eGFR, was lower
in patients than in controls.
Neo/Cr levels were higher in patients than in controls. The levels
of other investigated inflammatory variables were higher in CHF pa-
tients compared to controls, with the exception of serum CRP levels,
that were similar between groups (Table 2). Only Neo/Cr levels corre-
lated significantly with LVEDVi values (R=0.29, p=0.006).
Neopterin, clinical and echocardiographic variables in CHF patients
Patients were distributed according tertiles of Neo/Cr levels as de-
scribed in Table 3. The Neo/Cr levels range from 66 to 155 μmol/mol
in the first tertile, from 157 to 225 μmol/mol in the second tertile, and
from 226 to 811 μmol/mol in the third tertile. The median Neo/Cr
level of patients in the first tertile was comparable to that of controls,
while the median Neo/Cr levels of patients in the second and third
tertiles were higher with respect to that of controls (p=0.002 and
pb0.001, respectively).
Increasing Neo/Cr levels were significantly associated with LVEDVi
and NT-proBNP (Table 3), with the highest tertile of Neo/Cr levels
seen with the highest LVEDVi and NT-proBNP levels. Patients with se-
verely abnormal LV dimension (LVEDVi≥97 mL/m2) were 8 (25%) in
the first tertile, 17 (50%) in the second tertile, and 17 (53%) in the
third tertile of Neo/Cr levels (81% of patients with severely abnormal
LV dimension were in the second and third tertile).
Statin treatment, and the frequencies of male gender and NYHA
class I, was significantly decreased according to the increment of
Neo/Cr levels, while diuretic treatment was significantly increased
according to the increment of Neo/Cr levels by bivariate analysis
(Table 3).
Etiology, cardiovascular risk factors and renal function, assessed
by creatinine clearance, were not associated to Neo/Cr levels.OR 95% CI P
III (n=32)
57 (50–63) 1.003 0.972 1.035 0.851
23 (72) 0.316 0.115 0.871 0.026
25 (22–28) 0.965 0.892 1.043 0.365
99 (80–154) 1.012 1.004 1.020 0.004
72 (57–122) 1.009 0.999 1.019 0.102
2 (6) 0.077 0.019 0.321 b0.001
11 (34) 0.298 0.089 0.993 0.049
10 (31) 0.419 0.119 1.472 0.175
9 (28) 1.000 - -
14 (44) 0.615 0.293 1.290 0.199
21 (66) 1.223 0.574 2.605 0.603
26 (81) 1.145 0.471 2.781 0.765
11 (34) 0.302 0.140 0.654 0.002
17 (55) 0.869 0.408 1.853 0.717
27 (84) 3.501 1.478 8.293 0.004
4 (13) 0.749 0.236 2.381 0.624
14 (45) 1.285 0.596 2.771 0.522
9 (28) 1.275 0.552 2.944 0.569
75 (66–104) 0.991 0.981 1.001 0.110
2296 (820–3879) 1.000 1.000 1.001 0.001
0.30 (0.20–0.80) 2.158 1.082 4.301 0.029
2.97 (1.39–6.11) 1.048 0.996 1.103 0.079
4.70 (3.10–7.60) 1.273 1.071 1.512 0.006
221 (103–257) 1.003 0.999 1.007 0.172
183 (166–215) μmol/mol; III (third) tertile: 321 (249–469) μmol/mol.
Fig. 1. Grade of LVEDVi (A) and IL-8 levels (B) according to tertiles of Neo/Cr levels in chronic heart failure patients. Tertiles of Neo/Cr levels (μmol/mol): I, 126 (107–142); II, 183
(166–215); III: 321 (249–469).
97R. Caruso et al. / Clinical Biochemistry 46 (2013) 94–98Neopterin and inflammatory variables in HF patients
Among inflammatory variables, only serum CRP and plasma IL-8
levels increased according to neopterin levels, while sICAM-1 levels
were comparable among CHF patients with different neopterin levels
(Table 3). The IL-6 levels increased according to neopterin levels but
only with a trend by bivariate analysis (Table 3).
Multivariate analysis
All the variables that reached the significance level pb0.05 were en-
tered into the final multivariable ordinal regressionmodel. The only pa-
rameters independently associated with neopterin levels were LVEDVi
values (OR 1.014, 95% CI 1.002–1.026, p=0.024, Fig. 1A), IL-8 levels
(OR 1.353, 95% CI 1.008–1.815, p=0.044, Fig. 1B), and male gender
(OR 0.257, 95% CI 0.067–0.977; p=0.046).
Discussion
The findings from our study indicate that, in CHF patients character-
ized from different clinical severity of HF and grade of LV remodeling,
higher neopterin levels are independently associatedwith increased di-
mensions of cardiac volume, echocardiographically defined by LVEDVi
values. Among inflammatory variables, only IL-8 levels resulted associ-
ated with neopterin levels in CHF patients.
Neopterin is a marker of macrophage/monocyte activation with a
putative physiological role in enhancing macrophage cytotoxicity
through its interactionswith reactive oxygen, nitrogen, chloride species
[18], and by its influence on myeloperoxidase activity [19]. Neopterin
has shown to promote oxidative stress-triggered apoptosis of vascular
smooth muscle cells and to promote plaque growth [20], even
suggesting its role in the inflammatory cascade promoting atherogene-
sis [21,22]. In isolated perfused rat hearts neopterin infusion favors
negative effects on cardiac performance by an enhancement of oxida-
tive stress, as demonstrated by co-treatment with the antioxidant
N-acetylcysteine that attenuated the adverse effect of neopterin [23].
Previous study has demonstrated an inverse correlation between
neopterin levels and LV ejection fraction in patients with chronic stable
angina [24]. In our CHF patientswe demonstrate a relationship between
urine neopterin levels and LV remodeling, in particular with diastolic
enlargement of cardiac volume, independently from etiology and clini-
cal status of HF patients (NYHA class). Furthermore, patients with se-
verely abnormal LV diastolic dimension [17] were greater associated
with higher levels of neopterin. In addition, CHF patients with the
greatest concentration of circulating neopterin also showed the highest
levels of IL-8, a chemokine crucial onmonocyte recruitment and attrac-
tion on endothelial cells. Therefore the presence of high levels of IL-8
and of LVEDVi, in associationwith the severity of the levels of neopterin,
support a heightened state of immune activation in CHF patients andthe pathological role of monocyte on LV remodeling. As observed even
in acute coronary syndrome [12], C-reactive protein and NT-proBNP
levels weren't associated with neopterin in our CHF patients. These
data support the potential contribution of the determination of
neopterin for the monitoring of ventricular remodeling with respect
to C-reactive protein, a non-specific inflammatory biomarker, and
NT-proBNP, that reflects the wall stress of left ventricle.
Noteworthy, in the HF disease the activation of metalloproteinases
(MMPs) and alteration of extracellular matrix components are con-
sidered crucial mechanisms involved in cardiac structural changes
that deteriorates into a dilated eccentric pattern [2]. An abnormal
balance between MMPs activity and their tissue inhibitors, or an in-
creased activity of MMPs, appear to be involved in collagen scaffold
degradation, LV dilation, and to compromise cardiac systolic function
[25]. Several studies have even suggested that oxidative stress acts
properly on MMPs metabolism, favoring progression of cardiac re-
modeling [26,27].
Previous studies have demonstrated that neopterin concentration,
in patients at risk for atherosclerosis or with cancer, relates to their an-
tioxidant status [28,29]. Moreover, neopterin levels have been found to
relate with homocysteine, a pro-oxidant aminothiol deleterious for vas-
cular function [30]. Baseline serum neopterin and MMP-9 concentra-
tions are found associated with rapid progression of coronary artery
disease in patients with chronic stable angina pectoris [31]. As a matter
of fact inducible MMP-9, a crucial MMP involved in LV remodeling, is
also expressed in the failing myocardium by infiltrating inflammatory
cells, such as monocytes [32]. In addition, in chronic renal failure the
dysregulation ofMMPs and their inhibitorswere found associated to in-
creased synthesis of neopterin [33]. Therefore, the association found be-
tween LVEDVi and neopterin levels in CHF patients is suggestive of an
involvement of monocyte activation in LV remodeling probably by oxi-
dative stress induced-MMPs activation.
Neopterin monitoring in body fluids provide information on
current state of cellular immune response and frequently help to pre-
dict progression of several diseases with intensified monocyte/
macrophage activity [18,34]. In IDC patients, abnormal neopterin
levels were associated with the development of progressive HF and
death, suggesting that neopterin levels are related to HF severity
[35]. Other study reported that plasma levels of neopterin might pre-
dict adverse cardiovascular events in patients with coronary artery
disease, acute coronary syndromes or severe peripheral artery disease
[9]. In keeping with these reports, we provide evidence that
neopterin levels are associated to LVEDVi values in CHF patients
supporting neopterin determination as useful tool to evaluate the
progression of LV remodeling. Moreover, in the present study,
neopterin levels were measured in biological samples easily accessi-
ble, such as samples of urine, and assessed by a fast and cheap HPLC
technique, with a procedure that lasts less than 15 minutes/sample.
Therefore, the measurement of neopterin, as inflammatory and
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stratification and to follow disease progression in CHF patients.
Study limitations
Failure to ascertain the levels of metalloproteinases is a limitation
of the study. The assessment of MMPs levels according to neopterin
levels might provide more accurate information on the role of
neopterin in LV remodeling. However, circulating levels of MMPs do
not always reflect the expression of cardiac MMPs.
Conclusions
In conclusion, an independent association between urine neopterin
levels and LV end-diastolic volume valueswas observed in CHF patients
with different HF clinical severity. The increment of IL-8 levels,
according with neopterin levels, suggests that monocyte activation is
involved in adverse LV remodeling. The clinical utility of neopterin as-
sessment in monitoring HF progression merits evaluation. Long-term
evaluation of LV remodeling progression might identify neopterin as
useful prognostic indicator.
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